Company profile for BeyondSpring

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Headquartered in New York, BeyondSpring Inc. (BeyondSpring) is a global, clinical-stage bio-pharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with University of Washington in de novo drug discovery using a ubiquitination platform. BeyondSpring's lead asset, Plinabulin, is in two Phase 3 global clinical trial as a direct anticanc...
Headquartered in New York, BeyondSpring Inc. (BeyondSpring) is a global, clinical-stage bio-pharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with University of Washington in de novo drug discovery using a ubiquitination platform. BeyondSpring's lead asset, Plinabulin, is in two Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and in the prevention of chemotherapy-induced neutropenia (CIN).

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
28 Liberty Street, 39th Floor, New York, NY 10005
Telephone
Telephone
+1 (646) 305-6387
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

Global ChemShow

Not Confirmed

envelop Contact Supplier

Global ChemShow

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/11/3203772/0/en/BeyondSpring-Announces-New-Analyses-of-DUBLIN-3-Phase-3-Study-Showing-Survival-Benefit-of-Plinabulin-Docetaxel-in-Post-Anti-PD-L-1-for-Non-squamous-EGFR-WT-NSCLC-and-a-Reduction-in.html

GLOBENEWSWIRE
11 Dec 2025

https://www.globenewswire.com/news-release/2025/08/13/3132541/0/en/BeyondSpring-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Corporate-Update-Accelerates-Momentum-with-Promising-Clinical-Advances-and-Strategic-Leadership-Appointment.html

GLOBENEWSWIRE
13 Aug 2025

https://www.globenewswire.com/news-release/2025/07/07/3110902/0/en/BeyondSpring-Publishes-Human-Clinical-Study-in-Med-Cell-Press-Showing-Plinabulin-Driven-Dendritic-Cell-Maturation-and-Tumor-Response-After-Prior-Checkpoint-Inhibitor-Failure.html

GLOBENEWSWIRE
07 Jul 2025

https://www.globenewswire.com/news-release/2025/06/03/3092584/0/en/BeyondSpring-Presents-Efficacy-Safety-Data-from-a-Phase-2-Study-of-Pembrolizumab-plus-Plinabulin-Docetaxel-in-Metastatic-NSCLC-after-Progressing-on-First-Line-Immune-Checkpoint-Inh.html

GLOBENEWSWIRE
03 Jun 2025

https://www.globenewswire.com/news-release/2025/05/28/3089325/0/en/BeyondSpring-Announces-Poster-Presentation-at-2025-ASCO-Annual-Meeting.html

GLOBENEWSWIRE
28 May 2025

https://www.globenewswire.com/news-release/2025/05/12/3079606/0/en/BeyondSpring-Reports-First-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html

GLOBENEWSWIRE
12 May 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty